| My Account | Subscribe | Contact Us | Donate |
Home
- The Edmonton Protocol and Me
- Olympia Dukakis and Her Husband Tackle Type 2
- Surfing with Type 1
- Behind the Wheel, But Still in Control
You can view the current or previous issues of Diabetes Health online, in their entirety, anytime you want.
Click Here To View
If you are a physician, educator and medical professional who focus on the treatment of diabetes, then this is the must have resource for you.
Finally! A fresh take on the “professional” journal. Each bi-monthly issue cuts through the jargon and presents the most important information you need to enhance your practice and assist your patients.
Each bi-monthly issue of Diabetes Health Professional is a self-contained handbook covering products, educational resources and the latest diabetes research, complimented by balanced editorial focused on medical news, drug prescription information, clinical practice recommendations and changing treatment options.
Each quarter we send you the latest, most updated research guides, product guides and educational resource guides available for you and your patients.
Each week the Diabetes Health E-Newsletter delivers links to the very latest in news, reviews, blogs and videos from Diabetes Health direct to your inbox.
As a subscriber you'll get access to the amazing Diabetes Health Digital Advantage™ so you can read the current issue of Diabetes Health magazine online wherever you are!
You can cancel your newsletter subscription at anytime by clicking "Unsubscribe" on the bottom of any newsletter you receive
Then enter your new email address in the above form and click "Subscribe"
Latest Research Articles
Candesartan not only reduced the occurrence of retinopathy in patients who entered the study free of the condition, but also slowed the progression of the disease in those who already had it.
Brits Report That Hypertension Drug Lowers Retinopathy Risk in Type 1s
According to the British public health organization Diabetes UK, a four-year study has shown that the drug candesartan reduces the chances of people with type 1 diabetes developing retinopathy by almost 20 percent.
These findings could lead to the first-time use of a drug therapy to treat retinopathy. Retinopathy, a common consequence of diabetes in which blood vessels in the eye begin to leak and then scar from the effects of high blood sugar, is currently treated with surgery or laser therapy.
Candesartan is a hypertension treatment commonly sold under the trade names Amias, Atacand, Blopress, and Ratacand by the drug companies AstraZeneca and Takeda Pharmaceuticals.
The researchers, from Imperial College in London, tracked more than 1,400 patients with type 1 diabetes, administering candesartan to 711 of them and a placebo to the remaining 710.
They noted that the drug not only reduced the occurrence of retinopathy in patients who entered the study free of the condition, but also slowed the progression of the disease in those who already had it.
Categories: Research, Type 1 Issues
Facebook
MySpace 
Digg
You May Also Be Interested In...
Click Here To View Or Post Comments
Oct 6, 2008 -
Email to a Friend
Send a link to this page to your friends and colleagues.